Skip to main content

A Phase 1b/2 Study Evaluating the Activity of Tinengotinib (TT-00420) in Combination with Androgen Receptor Signaling Inhibitors (ARSIs) in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)

Clinical Trial Grant
Duke Scholars

Awarded By

Memorial Sloan-Kettering Cancer Center

Start Date

March 7, 2025

End Date

February 23, 2029
 

Awarded By

Memorial Sloan-Kettering Cancer Center

Start Date

March 7, 2025

End Date

February 23, 2029